NIAGEN BIOSCIENCE INC (NAGE) Stock Price & Overview

NASDAQ:NAGE • US1710774076

5.06 USD
-0.04 (-0.78%)
At close: Mar 6, 2026
5.0787 USD
+0.02 (+0.37%)
After Hours: 3/6/2026, 8:00:02 PM

The current stock price of NAGE is 5.06 USD. Today NAGE is down by -0.78%. In the past month the price decreased by -1.36%.

NAGE Key Statistics

1-Month Range4.725 - 5.78
Current NAGE stock price positioned within its 1-month range.
Market Cap
403.839M
P/E
28.11
Fwd P/E
16.82
EPS (TTM)
0.18
Dividend Yield
N/A

NAGE Stock Performance

Today
-0.78%
1 Week
+0.20%
1 Month
-1.36%
3 Months
-21.55%
Longer-term
6 Months -46.23%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

NAGE Stock Chart

NIAGEN BIOSCIENCE INC / NAGE Daily stock chart

NAGE Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NAGE.


Chartmill TA Rating
Chartmill Setup Rating
NAGE Full Technical Analysis Report

NAGE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to NAGE. NAGE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NAGE Full Fundamental Analysis Report

NAGE Earnings

On March 4, 2026 NAGE reported an EPS of 0.03 and a revenue of 33.84M. The company beat EPS expectations (33.69% surprise) and beat revenue expectations (4.64% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported$0.03
Revenue Reported33.84M
EPS Surprise 33.69%
Revenue Surprise 4.64%
NAGE Earnings History

NAGE Forecast & Estimates

11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 218.5% is expected in the next year compared to the current price of 5.06.

For the next year, analysts expect an EPS growth of 67.17% and a revenue growth 20.36% for NAGE


Analysts
Analysts85.45
Price Target16.12 (218.58%)
EPS Next Y67.17%
Revenue Next Year20.36%
NAGE Forecast & Estimates

NAGE Groups

Sector & Classification

NAGE Financial Highlights

Over the last trailing twelve months NAGE reported a non-GAAP Earnings per Share(EPS) of 0.18. The EPS increased by 80% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)20.43M
Industry RankSector Rank
PM (TTM) 16.38%
ROA 20.82%
ROE 28.91%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-66.67%
Sales Q2Q%16.19%
EPS 1Y (TTM)80%
Revenue 1Y (TTM)N/A
NAGE financials

NAGE Ownership

Ownership
Inst Owners41.26%
Shares79.81M
Float52.52M
Ins Owners0.01%
Short Float %12.33%
Short Ratio7.5
NAGE Ownership

NAGE Competitors/Peers

The largest stocks on the US markets in the "Personal Care Products" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
KVUE KENVUE INC16.3234.967B
EL ESTEE LAUDER COMPANIES-CL A30.0934.679B
ELF ELF BEAUTY INC23.094.874B
IPAR INTERPARFUMS INC18.753.075B
COTY COTY INC-CL A4.782.112B
BRBR BELLRING BRANDS INC7.71.991B
EPC EDGEWELL PERSONAL CARE CO8.36985.792M
OLPX OLAPLEX HOLDINGS INC13.79977.902M
NATR NATURES SUNSHINE PRODS INC24.57452.2M
NUS NU SKIN ENTERPRISES INC - A5.32373.425M
USNA USANA HEALTH SCIENCES INC8.96332.696M
HNST HONEST CO INC/THE36.67328.412M

About NAGE

Company Profile

NAGE logo image Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.

Company Info

NIAGEN BIOSCIENCE INC

10900 Wilshire Blvd Suite 600

Los Angeles CALIFORNIA US

Employees: 104

NAGE Company Website

NAGE Investor Relations

Phone: 13103886706

NIAGEN BIOSCIENCE INC / NAGE FAQ

What does NAGE do?

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.


Can you provide the latest stock price for NIAGEN BIOSCIENCE INC?

The current stock price of NAGE is 5.06 USD. The price decreased by -0.78% in the last trading session.


What is the dividend status of NIAGEN BIOSCIENCE INC?

NAGE does not pay a dividend.


What is the ChartMill rating of NIAGEN BIOSCIENCE INC stock?

NAGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the analyst forecast for NAGE stock?

11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 218.5% is expected in the next year compared to the current price of 5.06.


What is the GICS sector and industry of NAGE stock?

NIAGEN BIOSCIENCE INC (NAGE) operates in the Consumer Staples sector and the Personal Care Products industry.


What is NIAGEN BIOSCIENCE INC worth?

NIAGEN BIOSCIENCE INC (NAGE) has a market capitalization of 403.84M USD. This makes NAGE a Small Cap stock.